Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.
Adenovirus vectors with E1 deleted of the human serotype 5 (AdHu5) and the chimpanzee serotype 68 (AdC68) expressing the glycoprotein of the Evelyn Rokiniki Abelseth strain of rabies virus were tested upon oral application for induction of systemic and mucosal transgene product-specific antibody responses in mice. Both vectors induced systemic and mucosal antibodies to rabies virus, including virus-neutralizing antibodies and protection against a severe intracerebral challenge with a mouse-adapted strain of rabies virus. Pre-existing immunity of AdHu5 virus, which dampens induction of transgene product-specific immunity elicited by AdHu5 vectors given systemically did not impair the response induced by oral vaccination. Oral priming-boosting regimens with either heterologous or homologous adenoviral vectors used sequentially increased both mucosal and systemic antibody titers to rabies virus [corrected]
D000256:Adenoviridae / Q000235:genetics* / Q000276:immunology*; D000284:Administration, Oral; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000276:immunology; D005260:Female; D005822:Genetic Vectors; D051379:Mice; D008810:Mice, Inbred C57BL; D008813:Mice, Inbred ICR; D009500:Neutralization Tests; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000276:immunology*; D019076:Transgenes; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology*
D000914:Antibodies, Viral; D011819:Rabies Vaccines; D014614:Vaccines, Synthetic